PRINCETON, NJ -- (MARKET WIRE) -- January 17, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced results of a Phase 2a proof-of-concept study of oral Hivenyl™ in the treatment of moderate to severe itching related to atopic dermatitis which indicate that Hivenyl significantly reduces itch symptoms without signs of sedation. Hivenyl is an oral formulation of vapitadine dihydrochloride, a novel antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis.
